Novel EGFR antibodies overcome acquired resistance
Resistance to targeted cancer therapies remains a major clinical challenge. But what if antibodies could be engineered to recognize the very mutations that allow tumor cells to escape treatment? In a collaboration between the University of Stuttgart, TU Braunschweig and YUMAB, researchers developed a novel human EGFR antibody that combines high affinity with the ability […]
Novel NKG2D-targeting bispecific antibodies improve B cell lymphoma killing
In collaboration with the universities of Kiel, Munich, and Braunschweig, a novel bispecific antibody CD20xNKG2D was developed to enhance lymphocyte recruitment and mediate killing of B cell lymphoma cells. Read more
PROxAbs: Next generation PROTACs to access difficult targets
In collaboration with YUMAB, scientists from Merck KGaA have developed a PROTAC-Antibody shuttle (PROxAb) to improve efficacy and therapeutic applicability of PROTACs. Read more